Related Experiment Video

Updated: May 22, 2026

Measuring Psoriasis Severity at Home
02:28

Measuring Psoriasis Severity at Home

Published on: March 1, 2024

Cardiovascular Risk and Psoriasis: the Role of Biologic Therapy

L Puig1

  • 1Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Barcelona, España.

Actas Dermo-Sifiliograficas
|May 18, 2012
PubMed

Insights

Psoriasis patients have higher cardiovascular risks due to chronic inflammation. Biologic therapies may reduce this risk, but careful monitoring for adverse cardiovascular events is essential.

Area of Science:

  • Dermatology
  • Cardiology
  • Immunology

Background:

  • Psoriasis is linked to increased cardiovascular risk factors, including myocardial infarction and stroke.
  • Chronic systemic inflammation in psoriasis contributes to its role as an independent cardiovascular disease risk factor.
  • Biologic therapies offer improved psoriasis control and may reduce cardiovascular risk, similar to rheumatoid arthritis.

Purpose of the Study:

  • To review current scientific evidence on the relationship between psoriasis, cardiovascular risk, and biologic therapies.
  • To discuss the potential cardiovascular benefits and risks associated with biologic treatments for psoriasis.

Main Methods:

  • Review of epidemiological evidence and clinical trial data.
  • Analysis of studies investigating biologic therapies targeting IL-12/IL-23 pathways.
  • Examination of adverse event reports related to biologic use in psoriasis patients.

Main Results:

  • Biologic therapies show promise in potentially lowering cardiovascular risk in psoriasis patients.
  • Tumor necrosis factor inhibitors require caution in patients with advanced heart failure.
  • Clinical trials of IL-12/IL-23 inhibitors (briakinumab, ustekinumab) noted numerical imbalances in major cardiovascular events.

Conclusions:

  • Biologic therapies represent a significant advancement in psoriasis treatment with potential cardiovascular benefits.
  • Careful patient selection and monitoring are crucial when using biologic drugs, especially in those with pre-existing cardiovascular conditions.
  • Further research is needed to fully elucidate the cardiovascular safety profile of specific biologic agents in psoriasis management.

Related Concept Videos

Psychoneuroimmunology: Cardiovascular Disease01:27

Psychoneuroimmunology: Cardiovascular Disease

Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...